banner
grahamabra.bsky.social
@grahamabra.bsky.social
Nephrologist @StanfordNeph, Chair @HDAE_Official, Director Social Media @HemodialysisInt, Defender of the 4 nephrons.
Reposted
6/ 📖 Intro
⚡ SGLT2 inhibitors, first made for glucose control, surprised us with strong renal + CV protection 💥 Their small, reversible eGFR dip (like RASi) hinted at the mechanism: more Na⁺ to the macula densa → restored tubuloglomerular feedback → ⬇️ glomerular pressure → nephroprotection. 🧬
November 20, 2025 at 6:47 PM
Reposted
November 13, 2025 at 1:07 AM
It is now a much more modifiable risk factor than in the pre-GLP1 RA era

Seems to make sense to address prior to transplant given the limited resource of organs

Gives the surgery/healing and long term outcome the best shot
November 13, 2025 at 1:08 AM
I have not, COL4A3 and 4 heterozygotes
November 9, 2025 at 9:28 PM
Agreed - already have some proactive DMI folks on Finerenone - has been safe and lowers proteinuria in my hands
November 7, 2025 at 8:13 PM
I think many of us like to practice this way - conservative management of AKI-D but hospital discharge planners and teams often are inpatient for a schedule for discharge

Monitoring and Management of AKI-D in our outpatient HD centers is messy
November 7, 2025 at 7:56 PM